Personalis, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-01-05: Study NCT06225505; Company role Collaborator; Phase Not applicable; Status Recruiting.
- 2025-09-30: Study NCT06923527; Company role Collaborator; Phase Phase 2; Status Recruiting.
- 2024-11-25: Study NCT06705361; Company role Collaborator; Phase Not applicable; Status Not yet recruiting.
- 2023-11-09: Study NCT06230185; Company role Lead sponsor; Phase Observational; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | NCT06225505 Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) | Collaborator Lead: Institut Curie | Not applicable | Recruiting | Triple Negative Breast Cancer | 450 | 2031-08-03 |
| 2025-09-30 | NCT06923527 Circulating Tumor DNA | Collaborator Lead: Yale University | Phase 2 | Recruiting | ER+ Breast Cancer | 50 | 2027-09 |
| 2024-11-25 | NCT06705361 Ice Bag, TR Band, and Air Compression Effects on Radial Line Removal Outcomes in Open Heart Surgery: A Clinical Trial | Collaborator Lead: University of Baghdad | Not applicable | Not yet recruiting | Cardiac Disease | 104 | 2025-03-25 |
| 2023-11-09 | NCT06230185 CtDNA Based MRD Testing for NAC Monitoring in TNBC | Lead sponsor | Observational | Recruiting | TNBC - Triple-Negative Breast Cancer; Minimal Residual Disease | 422 | 2025-12-31 |
| 2023-07-12 | NCT05414032 Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC | Collaborator Lead: University Health Network, Toronto | Phase 2 | Recruiting | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | 102 | 2028-07 |
| 2023-04-18 | NCT05695976 GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM | Collaborator Lead: Duke University | Observational | Suspended | Glioblastoma; Glioma, Malignant | 100 | 2029-01 |
| 2022-07-20 | NCT05197322 NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer | Collaborator Lead: University College, London | Phase 2 | Active not recruiting | Adenocarcinoma of the Colon | 88 | 2029-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |